Colorectal Cancer[EB/OL]. https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review[J]. JAMA. 2021;325(7):669–85.

Article  CAS  PubMed  Google Scholar 

Bailey CR, George ML. Colorectal cancer surgery: is further research necessary?[J]. Anaesthesia. 2022;77(7):748–50.

Article  CAS  PubMed  Google Scholar 

Fricker LD. Proteasome inhibitor drugs[J]. Annu Rev Pharmacol Toxicol. 2020;60:457–76.

Article  CAS  PubMed  Google Scholar 

Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma[J]. Blood. 2019;134(16):1337–45.

Article  PubMed  PubMed Central  Google Scholar 

Gandolfi S, Laubach JP, Hideshima T, et al. The proteasome and proteasome inhibitors in multiple myeloma[J]. Cancer Metastasis Rev. 2017;36(4):561–84.

Article  CAS  PubMed  Google Scholar 

Chen ZL, Xie C, Zeng W, et al. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases[J]. Signal Transduct Target Ther. 2024;9(1):181.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang JP, He YM, Cui YL, et al. Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX/GSDME pathway[J]. Acta Pharmacol Sin. 2023;44(7):1464–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu P, Zhang X, Liu N, et al. Pyroptosis: mechanisms and diseases[J]. Signal Transduct Target Ther. 2021;6(1):128.

Article  PubMed  PubMed Central  Google Scholar 

Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11[J]. Nature. 2011;479(7371):117–21.

Article  CAS  PubMed  Google Scholar 

Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4[J]. Science. 2013;341(6151):1246–9.

Article  CAS  PubMed  Google Scholar 

Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS[J]. Nature. 2014;514(7521):187–92.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Chen X, Gueydan C, et al. Plasma membrane changes during programmed cell deaths[J]. Cell Res. 2018;28(1):9–21.

Article  CAS  PubMed  Google Scholar 

Wang X, Wang Y, Zhang W, et al. Biomimetic-gasdermin-protein-expressing nanoplatform mediates tumor-specific pyroptosis for cancer immunotherapy[J]. J Control Release. 2024;367:61–75.

Article  CAS  PubMed  Google Scholar 

Li F, Zhang XQ, Ho W, et al. mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy[J]. Nat Commun. 2023;14(1):4223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang Y, Tang Y, Huang B. Pyroptosis: A road to next-generation cancer immunotherapy[J]. Semin Immunol. 2023;68:101782.

Article  CAS  PubMed  Google Scholar 

Shah S, Dhawan V, Holm R, et al. Liposomes: Advancements and innovation in the manufacturing process[J]. Adv Drug Deliv Rev. 2020;154–155:102–22.

Article  PubMed  Google Scholar 

Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications[J]. Adv Drug Deliv Rev. 2013;65(1):36–48.

Article  CAS  PubMed  Google Scholar 

Cheng X, Gao J, Ding Y, et al. Multi-functional liposome: a powerful theranostic nano-platform enhancing photodynamic therapy[J]. Adv Sci (Weinh). 2021;8(16):e2100876.

Article  PubMed  Google Scholar 

Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned[J]. J Control Release. 2012;160(2):117–34.

Article  CAS  PubMed  Google Scholar 

Zahednezhad F, Saadat M, Valizadeh H, et al. Liposome and immune system interplay: Challenges and potentials[J]. J Control Release. 2019;305:194–209.

Article  CAS  PubMed  Google Scholar 

Van Niel G, D’angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol. 2018;19(4):213–28.

Article  PubMed  Google Scholar 

Liang Y, Duan L, Lu J, et al. Engineering exosomes for targeted drug delivery[J]. Theranostics. 2021;11(7):3183–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elsharkasy OM, Nordin JZ, Hagey DW, et al. Extracellular vesicles as drug delivery systems: Why and how?[J]. Adv Drug Deliv Rev. 2020;159:332–43.

Article  CAS  PubMed  Google Scholar 

Rayamajhi S, Nguyen TDT, Marasini R, et al. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery[J]. Acta Biomater. 2019;94:482–94.

Article  CAS  PubMed  Google Scholar 

Lin Y, Wu J, Gu W, et al. Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs[J]. Adv Sci (Weinh). 2018;5(4):1700611.

Article  PubMed  Google Scholar 

Sato YT, Umezaki K, Sawada S, et al. Engineering hybrid exosomes by membrane fusion with liposomes[J]. Sci Rep. 2016;6:21933.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems[J]. J Control Release. 2021;329:894–906.

Article  CAS  PubMed  Google Scholar 

Ruan J, Xia S, Liu X, et al. Cryo-EM structure of the gasdermin A3 membrane pore[J]. Nature. 2018;557(7703):62–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity[J]. Trends Cell Biol. 2020;30(9):695–704.

Article  CAS  PubMed  Google Scholar